SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-17-127264
Filing Date
2017-04-18
Accepted
2017-04-18 15:19:58
Documents
7
Period of Report
2017-05-31
Effectiveness Date
2017-04-18

Document Format Files

Seq Description Document Type Size
1 DEF 14A d334253ddef14a.htm DEF 14A 669233
2 GRAPHIC g322141g21w10.jpg GRAPHIC 33374
3 GRAPHIC g322141g38l86.jpg GRAPHIC 23213
4 GRAPHIC g322141g54t09.jpg GRAPHIC 22635
5 GRAPHIC g322141g77a13.jpg GRAPHIC 23954
6 GRAPHIC g334253g21w10.jpg GRAPHIC 33374
7 GRAPHIC g334253g47k82.jpg GRAPHIC 25755
  Complete submission text file 0001193125-17-127264.txt   893889
Mailing Address AESCHENVORSTADT 36 BASEL V8 4051
Business Address AESCHENVORSTADT 36 BASEL V8 4051 6173154600
CRISPR Therapeutics AG (Filer) CIK: 0001674416 (see all company filings)

IRS No.: 473173478 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37923 | Film No.: 17766910
SIC: 2836 Biological Products, (No Diagnostic Substances)